|

Dapagliflozin Clinical Trials

11 actively recruiting trials across 2 locations

Also known as: FORXIGA, Farxiga, Forxiga, farxiga

Pipeline

Phase 1: 2Phase 3: 4Phase 4: 2Phase 1/2: 1Phase 2/3: 1

Top Sponsors

Washington University School of Medicine2
Xiangtan Central Hospital1
University of Sao Paulo1
The University of Texas Health Science Center at San Antonio1
The George Institute1

Indications

Heart Disease5
Cancer4
Diabetes3
Heart Failure3
STEMI1

Other8 trials

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

Phase 4

CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL

Phase 3

Dapagliflozin in Depression

Phase 1/2

Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

Phase 4

Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome

Phase 3

Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes

Phase 2/3

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Phase 3

Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients

Phase 3

St Louis, Missouri2 trials

Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

Washington University School of Medicine

Phase 1

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Washington University School of Medicine/St. Louis Children's Hospital

Phase 1

San Antonio, Texas1 trial

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

The University of Texas Health Science Center at San Antonio

N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.